FindTrial
Sign In

A Phase 2 Trial of ALIMTA (LY231514, Pemetrexed) Plus Oxaliplatin Administered Every 21 Days for First-Line Treatment of Patients With Advanced Colorectal Cancer.

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00034619
Enrollment
Unknown
Registered
2002-05-02
Start date
Unknown
Completion date
Unknown
Last updated
2006-07-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer

Brief summary

The purpose of this study is to assess the antitumor activity of ALIMTA plus Oxaliplatin combination therapy in patients with previously untreated advanced colorectal cancer

Interventions

DRUGALIMTA
DRUGOxaliplatin

Sponsors

Eli Lilly and Company
Lead SponsorINDUSTRY

Study design

Primary purpose
TREATMENT

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Diagnosis of primary cancer of the colon or rectum * Must have measurable disease * Must be able to comply with study procedure

Exclusion criteria

* Prior chemotherapy for advanced disease * Pregnancy or lactation * Candidates for surgical resection of one or more metastatic foci * Second primary cancer * Inability to take folic acid or vitamin B12

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026